echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Yuyue announced its annual results, doubled profits

    Yuyue announced its annual results, doubled profits

    • Last Update: 2021-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network News on April 20 
     
    Profit increased by 136%
     
    Recently, Yuyue Medical released its 2020 annual report.
    During the reporting period, Yuyue Medical achieved total operating income of 6.
    726 billion yuan, a year-on-year increase of 45.
    08%; operating profit of 2.
    010 billion yuan, a year-on-year increase of 136.
    46%; net profit attributable to shareholders of listed companies 17.
    59 100 million yuan, an increase of 133.
    74% year-on-year.
     
    The annual report shows that during the reporting period, Yuyue Medical used more product orders for advance payment and cash settlement, and the company's sales collection was properly controlled.
    Operating cash flow increased by 360.
    90% compared with the same period last year, and accounts receivable decreased by 43.
    87 compared with the end of last year.
    %.
     
      It is understood that Yuyue Medical is a company whose main business is to provide home medical equipment, medical clinical products and related medical services.
    Its products are mainly concentrated in medical breathing and oxygen supply, home medical treatment and chronic disease management, inside and outside hospitals.
    Disinfection and control, surgical and ophthalmic instruments, and traditional Chinese medicine instruments.
     
      According to the annual report, in 2020, the main products of Yuyue Medical's household sector will grow rapidly.
    Among them, electronic sphygmomanometer products have increased by more than 35% year-on-year, blood glucose meters and test strip products have increased by more than 30% year-on-year, and AED products have increased by 20% year-on-year.
    In the breathing and oxygen supply sector, the domestic and overseas business development of oxygen concentrator products continued to increase, with a year-on-year growth rate of 40%, and the demand for ventilators was rapidly increasing due to the epidemic.
     
      Yuyue Medical’s clinical sector’s sensory control product business has further accelerated its growth.
    The subsidiary achieved operating income of 957 million yuan, a year-on-year increase of 53.
    13%, and realized a net profit of 262 million yuan, a year-on-year increase of 64.
    71%.
     
      However, some businesses have declined: although the business volume of nebulizers, wheelchairs, rehabilitation products and other products has recovered to a certain extent, there are still different proportions of declines.
    The production automation upgrade and lean work of the surgical instrument business was affected by the abnormal medical treatment during the reporting period, and the sales scale still declined to a certain extent.
     
      The latest plan is announced, focusing on the development of three areas
     
      The epidemic has a significant effect on the sales of Yuyue medical products.
    Today (April 19), Yuyue Medical released the "Investor Relations Activity Record", which shows that in 2020, its main epidemic-related products such as forehead guns will be released in 2018.
    On the market, 500,000 units will be sold in 2019, and the sales of forehead guns affected by the epidemic will increase significantly in 2020, exceeding 4 million units.
     
      In the domestic market where the epidemic has subsided, in 2020, taking the JD platform as an example, the company's oxygen generator product sales growth rate exceeded 40%.
     
      In addition, after the change of management, Yuyue Medical has been making overall strategic planning for the future.
    In the future, respiration, blood sugar, and sensory control are the three key areas for its efforts.
     
      According to reports, these three tracks have a large market space and low domestic penetration.
    The internal and external markets can form a good interaction and have a good product foundation.
     
      In terms of benchmarking foreign countries, Dekang in the blood sugar field, ResMed in the respiratory field and Yikang in the sensory control field are all listed companies with a market value of 100 billion yuan.
    Yuyue Medical will continue to launch on these three tracks through self-research and mergers and acquisitions.
    New product.
     
      According to data from China Industry Information Network, the current global blood glucose monitoring system market has a capacity of more than 15 billion U.
    S.
    dollars, and my country's blood glucose monitoring system market is about 8 billion.
    After calculation, it is estimated that the compound growth rate of the blood glucose testing market in the next three years is close to 20%, and it will reach 15.
    5 billion in 2021.
     
      The blood glucose market has a low penetration rate and still has great potential.
    According to the International Diabetes Federation, approximately 382 million adults worldwide suffer from diabetes.
    In 2016, there were approximately 114 million diabetic patients in China, ranking first in the world.
     
      In 2016, the number of diabetic patients in my country increased by about 24 million compared with 2011, with an average annual increase of 5 million.
    At present, the incidence of diabetes in my country is about 11.
    6%, of which 62% have abnormal blood sugar, but only 25% receive treatment, and the frequency of monitoring is even more difficult to meet the standard.
     
      In addition, my country's ventilator market is also showing an accelerated development trend.
    With the rise of medical equipment sales in e-commerce channels in recent years, the purchase channels of ventilators have become more diversified, and the entire industry has shown an accelerating trend year by year.
    In the next few years, the overall growth rate of the ventilator industry is expected to increase to more than 30%.
    Medical Network News on April 20 
     
      Profit increased by 136%
     
      Recently, Yuyue Medical released its 2020 annual report.
    During the reporting period, Yuyue Medical achieved total operating income of 6.
    726 billion yuan, a year-on-year increase of 45.
    08%; operating profit of 2.
    010 billion yuan, a year-on-year increase of 136.
    46%; net profit attributable to shareholders of listed companies 17.
    59 100 million yuan, an increase of 133.
    74% year-on-year.
     
      The annual report shows that during the reporting period, Yuyue Medical used more product orders for advance payment and cash settlement, and the company's sales collection was properly controlled.
    Operating cash flow increased by 360.
    90% compared with the same period last year, and accounts receivable decreased by 43.
    87 compared with the end of last year.
    %.
     
      It is understood that Yuyue Medical is a company whose main business is to provide home medical equipment, medical clinical products and related medical services.
    Its products are mainly concentrated in medical breathing and oxygen supply, home medical treatment and chronic disease management, inside and outside hospitals.
    Disinfection and control, surgical and ophthalmic instruments, and traditional Chinese medicine instruments.
     
      According to the annual report, in 2020, the main products of Yuyue Medical's household sector will grow rapidly.
    Among them, electronic sphygmomanometer products have increased by more than 35% year-on-year, blood glucose meters and test strip products have increased by more than 30% year-on-year, and AED products have increased by 20% year-on-year.
    In the breathing and oxygen supply sector, the domestic and overseas business development of oxygen concentrator products continued to increase, with a year-on-year growth rate of 40%, and the demand for ventilators was rapidly increasing due to the epidemic.
     
      Yuyue Medical’s clinical sector’s sensory control product business has further accelerated its growth.
    The subsidiary achieved operating income of 957 million yuan, a year-on-year increase of 53.
    13%, and realized a net profit of 262 million yuan, a year-on-year increase of 64.
    71%.
     
      However, some businesses have declined: although the business volume of nebulizers, wheelchairs, rehabilitation products and other products has recovered to a certain extent, there are still different proportions of declines.
    The production automation upgrade and lean work of the surgical instrument business was affected by the abnormal medical treatment during the reporting period, and the sales scale still declined to a certain extent.
     
      The latest plan is announced, focusing on the development of three areas
     
      The epidemic has a significant effect on the sales of Yuyue medical products.
    Today (April 19), Yuyue Medical released the "Investor Relations Activity Record", which shows that in 2020, its main epidemic-related products such as forehead guns will be released in 2018.
    On the market, 500,000 units will be sold in 2019, and the sales of forehead guns affected by the epidemic will increase significantly in 2020, exceeding 4 million units.
     
      In the domestic market where the epidemic has subsided, in 2020, taking the JD platform as an example, the company's oxygen generator product sales growth rate exceeded 40%.
     
      In addition, after the change of management, Yuyue Medical has been making overall strategic planning for the future.
    In the future, respiration, blood sugar, and sensory control are the three key areas for its efforts.
     
      According to reports, these three tracks have a large market space and low domestic penetration.
    The internal and external markets can form a good interaction and have a good product foundation.
     
      In terms of benchmarking foreign countries, Dekang in the blood sugar field, ResMed in the respiratory field and Yikang in the sensory control field are all listed companies with a market value of 100 billion yuan.
    Yuyue Medical will continue to launch on these three tracks through self-research and mergers and acquisitions.
    New product.
     
      According to data from China Industry Information Network, the current global blood glucose monitoring system market has a capacity of more than 15 billion U.
    S.
    dollars, and my country's blood glucose monitoring system market is about 8 billion.
    After calculation, it is estimated that the compound growth rate of the blood glucose testing market in the next three years is close to 20%, and it will reach 15.
    5 billion in 2021.
     
      The blood glucose market has a low penetration rate and still has great potential.
    According to the International Diabetes Federation, approximately 382 million adults worldwide suffer from diabetes.
    In 2016, there were approximately 114 million diabetic patients in China, ranking first in the world.
     
      In 2016, the number of diabetic patients in my country increased by about 24 million compared with 2011, with an average annual increase of 5 million.
    At present, the incidence of diabetes in my country is about 11.
    6%, of which 62% have abnormal blood sugar, but only 25% receive treatment, and the frequency of monitoring is even more difficult to meet the standard.
     
      In addition, my country's ventilator market is also showing an accelerated development trend.
    With the rise of medical equipment sales in e-commerce channels in recent years, the purchase channels of ventilators have become more diversified, and the entire industry has shown an accelerating trend year by year.
    In the next few years, the overall growth rate of the ventilator industry is expected to increase to more than 30%.
    Medical Network News on April 20 
     
      Profit increased by 136%
      Profit increased by 136%
     
      Recently, Yuyue Medical released its 2020 annual report.
    During the reporting period, Yuyue Medical achieved total operating income of 6.
    726 billion yuan, a year-on-year increase of 45.
    08%; operating profit of 2.
    010 billion yuan, a year-on-year increase of 136.
    46%; net profit attributable to shareholders of listed companies 17.
    59 100 million yuan, an increase of 133.
    74% year-on-year.
     
      The annual report shows that during the reporting period, Yuyue Medical used more product orders for advance payment and cash settlement, and the company's sales collection was properly controlled.
    Operating cash flow increased by 360.
    90% compared with the same period last year, and accounts receivable decreased by 43.
    87 compared with the end of last year.
    %.
     
      It is understood that Yuyue Medical is a company whose main business is to provide home medical equipment, medical clinical products and related medical services.
    Its products are mainly concentrated in medical breathing and oxygen supply, home medical treatment and chronic disease management, inside and outside hospitals.
    Disinfection and control, surgical and ophthalmic instruments, and traditional Chinese medicine instruments.
     
      According to the annual report, in 2020, the main products of Yuyue Medical's household sector will grow rapidly.
    Among them, electronic sphygmomanometer products have increased by more than 35% year-on-year, blood glucose meters and test strip products have increased by more than 30% year-on-year, and AED products have increased by 20% year-on-year.
    In the breathing and oxygen supply sector, the domestic and overseas business development of oxygen concentrator products continued to increase, with a year-on-year growth rate of 40%, and the demand for ventilators was rapidly increasing due to the epidemic.
     
      Yuyue Medical’s clinical sector’s sensory control product business has further accelerated its growth.
    The subsidiary achieved operating income of 957 million yuan, a year-on-year increase of 53.
    13%, and realized a net profit of 262 million yuan, a year-on-year increase of 64.
    71%.
     
      However, some businesses have declined: although the business volume of nebulizers, wheelchairs, rehabilitation products and other products has recovered to a certain extent, there are still different proportions of declines.
    The production automation upgrade and lean work of the surgical instrument business was affected by the abnormal medical treatment during the reporting period, and the sales scale still declined to a certain extent.
     
      The latest plan is announced, focusing on the development of three areas
      The latest plan is announced, focusing on the development of three areas
     
      The epidemic has a significant effect on the sales of Yuyue medical products.
    Today (April 19), Yuyue Medical released the "Investor Relations Activity Record", which shows that in 2020, its main epidemic-related products such as forehead guns will be released in 2018.
    On the market, 500,000 units will be sold in 2019, and the sales of forehead guns affected by the epidemic will increase significantly in 2020, exceeding 4 million units.
     
      In the domestic market where the epidemic has subsided, in 2020, taking the JD platform as an example, the company's oxygen generator product sales growth rate exceeded 40%.
     
      In addition, after the change of management, Yuyue Medical has been making overall strategic planning for the future.
    In the future, respiration, blood sugar, and sensory control are the three key areas for its efforts.
     
      According to reports, these three tracks have a large market space and low domestic penetration.
    The internal and external markets can form a good interaction and have a good product foundation.
     
      In terms of benchmarking foreign countries, Dekang in the blood sugar field, ResMed in the respiratory field and Yikang in the sensory control field are all listed companies with a market value of 100 billion yuan.
    Yuyue Medical will continue to launch on these three tracks through self-research and mergers and acquisitions.
    New product.
     
      According to data from China Industry Information Network, the current global blood glucose monitoring system market has a capacity of more than 15 billion U.
    S.
    dollars, and my country's blood glucose monitoring system market is about 8 billion.
    After calculation, it is estimated that the compound growth rate of the blood glucose testing market in the next three years is close to 20%, and it will reach 15.
    5 billion in 2021.
     
      The blood glucose market has a low penetration rate and still has great potential.
    According to the International Diabetes Federation, approximately 382 million adults worldwide suffer from diabetes.
    In 2016, there were approximately 114 million diabetic patients in China, ranking first in the world.
     
      In 2016, the number of diabetic patients in my country increased by about 24 million compared with 2011, with an average annual increase of 5 million.
    At present, the incidence of diabetes in my country is about 11.
    6%, of which 62% have abnormal blood sugar, but only 25% receive treatment, and the frequency of monitoring is even more difficult to meet the standard.
     
      In addition, my country's ventilator market is also showing an accelerated development trend.
    With the rise of medical equipment sales in e-commerce channels in recent years, the purchase channels of ventilators have become more diversified, and the entire industry has shown an accelerating trend year by year.
    In the next few years, the overall growth rate of the ventilator industry is expected to increase to more than 30%.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.